A Phase II Trial of Intraperitoneal EGEN-001, An IL-12 Plasmid Formulated with PEG-PEI-Cholesterol Lipopolymer in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

OBJECTIVE: The purpose of this phase II trial was to evaluate the toxicity and antitumor activity of EGEN-001 in platinum resistant recurrent ovarian cancer. METHODS: Eligible patients had weekly IP infusion of EGEN-001 at a dose of 24 mg/m(2). Toxicity and antitumor activity were evaluated using CT...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Alvarez, Ronald D., Sill, Michael W., Davidson, Susan A., Muller, Carolyn Y., Bender, David P., DeBernardo, Robert L., Behbakht, Kian, Huh, Warner K.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4057915/
https://ncbi.nlm.nih.gov/pubmed/24708919
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2014.03.571
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados